Get started
Author

Nathan Hahn

Observed institution: Eli Lilly (United States)
ORCID: 0000-0003-0289-6261
Observed ORCID: 0000-0003-0289-6261
OpenAlex ID: A5044924677
Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis
2022 · Varsha Parthasarathy, Karen Cravero, et al. · Frontiers in Medicine · 34
PDF
Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis
2025 · Emma Guttman-Yassky, Zhe Sun, et al. · Dermatology and Therapy · 12
PDF
Serum Interleukin-13 and Caspase 8 are Elevated in Prurigo Nodularis
2023 · Teresa Ju, Angelina Labib, et al. · Acta Dermato Venereologica · 12
PDF
495 - Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
2024 · Emma Guttman-Yassky, Angela Okragly, et al. · British Journal of Dermatology · 3
42186 Prurigo nodularis blood signature is characterized by increases in IL-13 and caspase 8
2023 · Teresa Ju, Angelina Labib, et al. · Journal of the American Academy of Dermatology
PDF
Works count: 5
Citation count: 61
H-index: 3
I10-index: 3
Year
Topic
Type